Corcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript

Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, up 64% year over year and 33% sequentially; net income rose to $126.8 million from $19.7 million a year earlier, and diluted EPS was $1.01 versus $0.16. Lifyorli generated $91.4 million in revenue, up 92% from Q2, while management reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion and reported $43.7 million in common-stock repurchases. The company highlighted pipeline results and upcoming studies, with an FDA decision on relacorilant for Cushing’s syndrome expected by its Dec. 17, 2026 PDUFA date; the clinical findings and future revenue targets are management-reported or projected.

Analysis

CORT’s near-term setup is a launch-and-regulatory story, but the quarter does not yet establish a durable run rate. Lifyorli’s rapid uptake matters most if new starts convert to repeat prescribing and sustained treatment; management offered no quantified duration or refill data, so patient counts alone may overstate revenue visibility. The unchanged full-year outlook despite strong momentum is a reason to avoid extrapolating the latest quarter without checking Q4 guidance assumptions and the next filing. Higher launch SG&A may moderate near-term operating leverage; verify whether lower R&D spending reflects timing or a sustained change.

The Dec. 17 relacorilant decision is the main 1–3 month binary catalyst. Approval could expand the Cushing’s treatment funnel if ADA screening guidance turns into actual diagnoses and prescribing, but screening is not conversion, and the company’s multibillion-dollar targets are management projections—not established demand. The prior CRL and management’s reference to an FDA-requested analysis leave regulatory execution risk. Over 6–18 months, Lifyorli’s combination and earlier-line potential and the Cushing’s launch could broaden growth, while MASH, ALS and other oncology programs remain high-attrition pipeline options with meaningful data still ahead.

The call’s competitive framing around Genmab’s Rina-S is not enough to price a direct threat or benefit: management itself declined to assess the limited data and emphasized possible combinations. Treat it as a diligence trigger, not a thesis. Consensus may be over-weighting the headline growth and under-weighting the gap between launch activity and durable patient economics, plus the binary FDA event.

Key Decisions for Investors

• For existing CORT exposure, retain a measured core but avoid adding aggressively into the Dec. 17 decision without a defined event-risk limit; trim if the position has become oversized. Approval could remove a major overhang, while a delay or negative decision could reprice the Cushing’s opportunity quickly.
• Consider a small, defined-risk CORT call spread only if the premium and implied volatility make the event payoff attractive; otherwise wait until after the FDA decision. No price target is warranted without current valuation and options data.
• Before treating Lifyorli as a compounding launch, track repeat prescriptions, treatment duration, new patient starts, and the share of use in earlier approved lines. Fading repeat prescribing or a material Q4 shortfall versus the reiterated revenue range would weaken the thesis.
• Verify the relacorilant FDA outcome and label, including any restrictions, then monitor initial launch access and treatment-naive patient conversion. Approval alone would not validate management’s long-range revenue targets.
• Keep MASH, ALS, and broader oncology indications out of the base-case valuation until later-stage evidence arrives. Reassess if upcoming controlled-trial results fail to reproduce the preliminary signals or if Lifyorli uptake decelerates; assess Genmab’s Rina-S only when fuller efficacy and positioning data are available.